Buying Opportunity: Foreign Stock Drops 30% in One Month—Analyst Predicts Potential Rebound in Coming Weeks

• Why Did the "Ozempic Stock" Crash 30%—And Is This a Buying Opportunity?
• Beyond the Bounce: 9 Other International Stocks to Watch in August
• How to Access the Full International Stock Portfolio for Free
• Frequently Asked Questions

Looking for a short-term play in international markets this August? A beaten-down stock that plunged 30% last month might be your ticket. According to analyst Enzo Pacheco of Empiricus Research, the sharp decline presents a rare chance to "catch a rebound" soon. The stock in question? Novo Nordisk (N1VO34), Maker of the blockbuster diabetes/weight-loss drug Ozempic. While recent headwinds have battered the stock, Pacheco sees an overreaction—and a 10% portfolio allocation could capitalize on the bounce. Beyond this "Ozempic stock," the analyst's international portfolio reveals 9 other undervalued picks across sectors like tech. Here's why this dip might be worth buying.

Why Did the "Ozempic Stock" Crash 30%—And Is This a Buying Opportunity?

Novo Nordisk's recent tumble stems from a perfect storm: rising competition (notably from Eli Lilly), generic drug threats, lowered sales growth projections (now 8%-14% vs. prior 13%-21%), and a CEO transition. "The selloff had justification but went too far," argues Pacheco, who added the stock to Empiricus' model portfolio at a 10% weighting. Trading at 2025's discounted levels, Novo still dominates a growing market—making this a potential short-term "trade" rather than a long-term hold.

Beyond the Bounce: 9 Other International Stocks to Watch in August

Pacheco's global portfolio diversifies across sectors, with tech stocks taking center stage. "These companies aren’t just hype—they’re delivering real results," he notes. While specifics on the other 9 picks require accessing Empiricus' full report (free via Money Times), the broader strategy leans into:

• Undervalued growth stocks post-correction
• Sector diversification to mitigate risk
• Short-to-medium-term price catalysts

How to Access the Full International Stock Portfolio for Free

Empiricus publishes a monthly global stock picks report, and August’s edition—including detailed theses on all 10 stocks—is currently offered as a free download. Clicking the LINK below triggers an email with full access. No credit card required.

Frequently Asked Questions

Is Novo Nordisk a long-term investment after this drop?

Analysts view it primarily as a short-term rebound play given competitive pressures. Long-term holders should monitor Ozempic’s market share.

Why focus on international stocks now?

Dollar strength and sector rotations have created mispricings in quality foreign equities—especially in healthcare and tech.

How volatile are these recommendations?

While the portfolio includes stable players, positions like Novo Nordisk carry higher short-term risk. Always size accordingly.